62
Participants
Start Date
December 1, 2025
Primary Completion Date
October 1, 2027
Study Completion Date
October 1, 2028
CHO-A04
CHO-A04 will be given intravenously (IV) once weekly for 4 weeks as a treatment cycle.
Department of Oncology, National Taiwan University Hospital, Taipei
Lead Sponsor
Cho Pharma Inc.
INDUSTRY